Wang Yan, Zhang XiaoLi, Li Qin, Zhang Qing, Liu Jun
Department of Nuclear Medicine, The Second Affiliated Hospital, JiangXi Medical College, Nanchang University, Nanchang, China.
The First Affiliated Hospital, JiangXi Medical College, Nanchang University, Nanchang, China.
Front Genet. 2025 Apr 2;16:1399353. doi: 10.3389/fgene.2025.1399353. eCollection 2025.
Evidence on the relationship between thyroid function and hepatic fibrosis/cirrhosis are still unclear, with inconsistent conclusions. This Mendelian randomization (MR) study aimed to investigate the potential causal association between thyroid function and hepatic fibrosis/cirrhosis in order to provide new insights for improving prevention and control strategies for this disease.
Genome-wide association study (GWAS) data on exposures, which included hyperthyroidism, hypothyroidism, and thyroid-stimulating hormone (TSH), were extracted from the MRC Integrative Epidemiology Unit (MRC-IEU) (https://gwas.mrcieu.ac.uk/), and GWAS data for outcomes, including hepatic fibrosis/cirrhosis and chitinase-3-like protein 1 (CHI3L1), were obtained from the FinnGen consortium (https://www.finngen.fi/fi). Inverse variance weighted (IVW), weighted median, and MR-Egger methods were utilized to examine the causal association between thyroid function and the risk of hepatic fibrosis/cirrhosis. Cochran's Q test was used to assess the heterogeneity of instrumental variables (IVs), while MR-PRESSO and leave-one-out analyses were conducted for sensitivity analysis.
IVW estimates suggested that hypothyroidism had a potential causal association with higher odds of hepatic fibrosis/cirrhosis (OR = 1.247, 95% CI: 1.087-1.431). Leave-one-out results indicated that this potential causal relationship was relatively robust. In addition, we assessed the causal association between hypothyroidism and hepatic fibrosis/cirrhosis before and after removal of outliers with heterogeneity. After removing the outliers, the association was still significant (OR = 1.266, 95% CI: 1.082-1.482, = 0.0046).
Patients with hypothyroidism may have a higher risk of hepatic fibrosis/cirrhosis, and this finding may provide some references for the early screening and prevention of the disease. However, further studies are needed to explore the specific mechanisms by which hypothyroidism influences hepatic fibrosis/cirrhosis.
甲状腺功能与肝纤维化/肝硬化之间关系的证据仍不明确,结论不一致。这项孟德尔随机化(MR)研究旨在调查甲状腺功能与肝纤维化/肝硬化之间的潜在因果关联,以便为改进该疾病的预防和控制策略提供新见解。
从MRC综合流行病学单位(MRC-IEU)(https://gwas.mrcieu.ac.uk/)提取关于暴露因素(包括甲状腺功能亢进、甲状腺功能减退和促甲状腺激素(TSH))的全基因组关联研究(GWAS)数据,从芬兰基因联盟(https://www.finngen.fi/fi)获取包括肝纤维化/肝硬化和几丁质酶-3样蛋白1(CHI3L1)在内的结局指标的GWAS数据。采用逆方差加权(IVW)、加权中位数和MR-Egger方法检验甲状腺功能与肝纤维化/肝硬化风险之间的因果关联。使用Cochran's Q检验评估工具变量(IVs)的异质性,同时进行MR-PRESSO和留一法分析以进行敏感性分析。
IVW估计表明,甲状腺功能减退与肝纤维化/肝硬化几率较高存在潜在因果关联(OR = 1.247,95%CI:1.087 - 1.431)。留一法结果表明这种潜在因果关系相对稳健。此外,我们评估了去除具有异质性的异常值前后甲状腺功能减退与肝纤维化/肝硬化之间的因果关联。去除异常值后,该关联仍然显著(OR = 1.266,95%CI:1.082 - 1.482,P = 0.0046)。
甲状腺功能减退患者可能具有较高的肝纤维化/肝硬化风险,这一发现可能为该疾病的早期筛查和预防提供一些参考。然而,需要进一步研究以探索甲状腺功能减退影响肝纤维化/肝硬化的具体机制。